Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial ...